Objective: Go observe effects of Shenqi Fuxin Oral Liquid on plasma kaliuritic peptide （KP） . cardiac function and left ventricular replastisity. Methods: 80 cases of chronic cardiac functional insufficiency after myocardial infarction were randomly divided into treatment group （n = 44） and control group （n = 36）. Both groups were given the same routine treatment

and the treatment group was added with Shenqi Fuxin Oral Liquid and the control group with Captopril. Plasma K.P

endothelin-1 （ET-1） and atrial natriuretic polypeptide （ANP） before and after treatment were determined

and 6 months later

changes of the left ventricular replastisity and cardiac function were investigated by color ultrasound cardiogram. Results: Total effective rate was 86. 1% in the treatment group and 90. 3% in the control group with no significant difference between two groups （P > 0. 05）. After treatment the indexes of the cardiac replasticity and cardiac function in both groups improved significantly （P<0. 01） . and ANP and ET-1 levels significantly decreased as compared with those before treatment GP<0. 01 or P<0. 05). After treatment

KP level in the treatment group decreased significantly as compared with that before treatment （P<0. 05）

and in the control group it did not change significantly （P > 0.05）. Conclusion: Shenqi Fuxin Oral Liquid can decrease plasma KP level and has functions of arresting cardiac replasticity

improving cardiac function in the patient of chronic cardiac functional insufficiency after myocardial infarction.